ERBB2 and breast cancer: Our data revealed significant prognostic differences among immune subgroups of the luminal B subtypes but not the luminal A, basal, or HER2 subtypes (Figure 5—figure supplement 1C–F), highlighting that integrating our method with traditional classification may enable a more detailed stratification of breast cancer samples.